These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 9539347)

  • 1. Imaging the pre- and postsynaptic side of striatal dopaminergic synapses in idiopathic cervical dystonia: a SPECT study using [123I] epidepride and [123I] beta-CIT.
    Naumann M; Pirker W; Reiners K; Lange KW; Becker G; Brücke T
    Mov Disord; 1998 Mar; 13(2):319-23. PubMed ID: 9539347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.
    Wenning GK; Donnemiller E; Granata R; Riccabona G; Poewe W
    Mov Disord; 1998 May; 13(3):438-45. PubMed ID: 9613734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy.
    Knudsen GM; Karlsborg M; Thomsen G; Krabbe K; Regeur L; Nygaard T; Videbaek C; Werdelin L
    Eur J Nucl Med Mol Imaging; 2004 Dec; 31(12):1631-8. PubMed ID: 15583914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters.
    Seibyl JP; Laruelle M; van Dyck CH; Wallace E; Baldwin RM; Zoghbi S; Zea-Ponce Y; Neumeyer JL; Charney DS; Hoffer PB; Innis RB
    J Nucl Med; 1996 Feb; 37(2):222-8. PubMed ID: 8667048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.
    Ishikawa T; Dhawan V; Kazumata K; Chaly T; Mandel F; Neumeyer J; Margouleff C; Babchyck B; Zanzi I; Eidelberg D
    J Nucl Med; 1996 Nov; 37(11):1760-5. PubMed ID: 8917170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine transporter imaging with [123I]-beta-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease.
    Jeon B; Kim JM; Jeong JM; Kim KM; Chang YS; Lee DS; Lee MC
    J Neurol Neurosurg Psychiatry; 1998 Jul; 65(1):60-4. PubMed ID: 9667562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPECT-evaluation of the monoamine uptake site ligand [123I](1R)-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane ([123I]beta-CIT) in untreated patients with suspicion of Parkinson disease.
    Eising EG; Müller TT; Zander C; Kuhn W; Farahati J; Reiners C; Coenen HH
    J Investig Med; 1997 Oct; 45(8):448-52. PubMed ID: 9394097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
    Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB
    Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease.
    Scherfler C; Seppi K; Donnemiller E; Goebel G; Brenneis C; Virgolini I; Wenning GK; Poewe W
    Brain; 2005 Jul; 128(Pt 7):1605-12. PubMed ID: 15817519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormalities of dopaminergic neurotransmission in SCA2: a combined 123I-betaCIT and 123I-IBZM SPECT study.
    Boesch SM; Donnemiller E; Müller J; Seppi K; Weirich-Schwaiger H; Poewe W; Wenning GK
    Mov Disord; 2004 Nov; 19(11):1320-5. PubMed ID: 15390003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls.
    Eisensehr I; Linke R; Noachtar S; Schwarz J; Gildehaus FJ; Tatsch K
    Brain; 2000 Jun; 123 ( Pt 6)():1155-60. PubMed ID: 10825354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease.
    Asenbaum S; Brücke T; Pirker W; Podreka I; Angelberger P; Wenger S; Wöber C; Müller C; Deecke L
    J Nucl Med; 1997 Jan; 38(1):1-6. PubMed ID: 8998140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Baldwin RM; Zoghbi S; Zea-Ponce Y; Charney DS; van Dyck CH; Hoffer PB; Innis RB
    J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers.
    Staley JK; Krishnan-Sarin S; Zoghbi S; Tamagnan G; Fujita M; Seibyl JP; Maciejewski PK; O'Malley S; Innis RB
    Synapse; 2001 Sep; 41(4):275-84. PubMed ID: 11494398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the haloperidol tetrahydropyridine metabolite 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6- tetrahydropyridine on dopamine receptor and transporter binding. A nonhuman primate 123I-iodobenzamide and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane single photon emission computed tomographic study.
    Oliver DW; Dormehl IC; Van der Schyf CJ; Neumeyer JL; Hugo N; Keeve R; Rossouw NT; Müller-Gärtner HW; Castagnoli N
    Arzneimittelforschung; 1997 Jun; 47(6):692-9. PubMed ID: 9239444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous SPECT studies of pre- and postsynaptic dopamine binding sites in baboons.
    Dresel SH; Kung MP; Huang XF; Plössl K; Hou C; Meegalla SK; Patselas G; Mu M; Saffer JR; Kung HF
    J Nucl Med; 1999 Apr; 40(4):660-6. PubMed ID: 10210226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.
    Marek K; Innis R; van Dyck C; Fussell B; Early M; Eberly S; Oakes D; Seibyl J
    Neurology; 2001 Dec; 57(11):2089-94. PubMed ID: 11739831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional morphometry of the striatum in Parkinson's disease on three-dimensional surface display of 123I-beta-CIT SPECT data.
    Ichise M; Kim YJ; Erami SS; Ballinger JR; Vines D; Tanaka F; Lang AE
    J Nucl Med; 1999 Apr; 40(4):530-8. PubMed ID: 10210210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.